Palbociclib is the first CDK4/6 inhibitor approved for HR-positive, HER2-positive advanced breast cancer. The U.S. Food and Drug Administration (FDA) has approved palbociclib (Ibrance) in combination with trastuzumab (Herceptin), with or without pertuzumab (Perjeta),...
Afamitresgene autoleucel was granted full approval with an expanded indication for certain adult and pediatric patients with advanced synovial sarcoma. The U.S. Food and Drug Administration (FDA) has granted full approval to afamitresgene autoleucel...
Under new approval, the drug can be given with immunotherapy to help reduce risk of recurrence after surgery in patients with clear cell renal cell carcinoma. The U.S. Food and Drug Administration (FDA) has...
The FDA approved pivekimab sunirine-pvzy for the treatment of the rare blood cancer BPDCN. The U.S. Food and Drug Administration (FDA) has approved pivekimab sunirine-pvzy (Decnupaz) for the treatment of adult patients with blastic...
Datopotamab deruxtecan-dlnk was approved to treat PD-1/PD-L1 inhibitor-ineligible, advanced triple-negative breast cancer. The U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for adults with unresectable or metastatic triple-negative breast cancer (TNBC)...
The FDA has approved fam-trastuzumab deruxtecan-nxki for neoadjuvant or adjuvant treatment of HER2-positive early-stage breast cancer. The U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu) for two indications in adult patients...
The FDA has approved atezolizumab or atezolizumab and hyaluronidase-tqjs as adjuvant therapy for muscle-invasive bladder cancer. The U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant...
The BCL-2 inhibitor received accelerated approval for patients with relapsed or refractory mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sonrotoclax (Beqalzi) for the treatment of adult...
The bispecific antibody was approved for certain patients whose bile duct cancer harbors gene fusions that involve the neuregulin 1 gene. The U.S. Food and Drug Administration (FDA) approved zenocutuzumab-zbco (Bizengri) for the treatment...
Vepdegestrant is the first PROTAC approved for any cancer indication. The U.S. Food and Drug Administration (FDA) approved vepdegestrant (Veppanu) for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More